Anixa Biosciences Inc financial data

Symbol
ANIX on Nasdaq
Location
San Jose, CA
Fiscal year end
31 October
Latest financial report
10-K - Q3 2025 - 12 Jan 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 869% % -27%
Debt-to-equity 13% % 40%
Return On Equity -72% % -22%
Return On Assets -63% % -18%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33,376,690 shares 3.7%
Common Stock, Shares, Outstanding 33,013,829 shares 2.5%
Entity Public Float $85,116,394 USD -6%
Common Stock, Value, Issued $330,000 USD 2.5%
Weighted Average Number of Shares Outstanding, Basic 32,454 shares 1.7%
Weighted Average Number of Shares Outstanding, Diluted 32,454 shares 1.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $5,071,000 USD -21%
General and Administrative Expense $6,630,000 USD -11%
Costs and Expenses $11,701,000 USD -15%
Operating Income (Loss) $11,701,000 USD 15%
Net Income (Loss) Attributable to Parent $10,927,000 USD 13%
Earnings Per Share, Basic -0.34 USD/shares 13%
Earnings Per Share, Diluted -0.34 USD/shares 13%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $1,244,000 USD -2.1%
Cash, Cash Equivalents, and Short-term Investments $20,745,000 USD
Assets, Current $15,887,000 USD -26%
Operating Lease, Right-of-Use Asset $193,000 USD -16%
Assets $16,080,000 USD -26%
Accounts Payable, Current $165,000 USD -69%
Accrued Liabilities, Current $1,761,000 USD -9.5%
Liabilities, Current $1,967,000 USD -21%
Operating Lease, Liability, Noncurrent $163,000 USD -20%
Liabilities $2,130,000 USD -21%
Retained Earnings (Accumulated Deficit) $251,677,000 USD -4.5%
Stockholders' Equity Attributable to Parent $15,161,000 USD -24%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $13,950,000 USD -26%
Liabilities and Equity $16,080,000 USD -26%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,904,000 USD -26%
Net Cash Provided by (Used in) Financing Activities $17,000 USD -101%
Net Cash Provided by (Used in) Investing Activities $2,703,000 USD 1995%
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 33,013,829 shares 2.5%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $218,000 USD -363%
Deferred Tax Assets, Valuation Allowance $39,449,000 USD 4.5%
Deferred Tax Assets, Gross $39,449,000 USD 4.5%
Operating Lease, Liability $204,000 USD -12%
Lessee, Operating Lease, Liability, to be Paid $256,000 USD -18%
Operating Lease, Liability, Current $41,000 USD 41%
Lessee, Operating Lease, Liability, to be Paid, Year Two $64,000 USD 1.6%
Lessee, Operating Lease, Liability, to be Paid, Year One $63,000 USD 12%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $52,000 USD -35%
Lessee, Operating Lease, Liability, to be Paid, Year Three $66,000 USD 3.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 19,860 shares 0%
Unrecognized Tax Benefits $3,166,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $63,000 USD -4.5%
Additional Paid in Capital $266,508,000 USD 2.3%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 100 USD/shares 0%